Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma.
Hematology/oncology clinics of North America
Mantle cell lymphoma is an incurable B-cell malignancy. Treatment of young fit patients is particularly challenging, because careful consideration should be made when building a long-term treatment strategy that would provide longer remissions and increase patients' quality of life. Most young fit patients achieve long remissions with a combination of immunochemotherapy containing rituximab and high-dose cytarabine, followed by high-dose chemotherapy and autologous stem-cell transplantation. The addition of maintenance therapy with rituximab following autologous stem-cell transplantation prolongs the time to relapse and increases overall survival. Despite an intensive approach, late relapses are common and are usually treated with novel agents.
Earle A. Chiles Research Institute
Guy, Daniel and Kahl, Brad S, "Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma." (2020). Articles, Abstracts, and Reports. 3871.